Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of …,

A pivotal Phase 3 clinical trial of eprenetapopt and azacitidine for frontline treatment of TP53 mutant MDS has been completed and failed to meet the …, A pivotal Phase 3 clinical trial of eprenetapopt and azacitidine for frontline treatment of TP53 mutant MDS has been completed and failed to meet the …, Read More

Scroll to Top